
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CVAC | NASDAQ | USD | Real-time | |
1CVAC | Milan | EUR | Real-time | |
5CV | Frankfurt | EUR | Delayed | |
5CV | TradeGate | EUR | Delayed | |
5CV | Xetra | EUR | Delayed | |
5CV | Stuttgart | EUR | Delayed | |
CVAC | Vienna | EUR | Real-time |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Name | Age | Since | Title |
---|---|---|---|
Baron Jean Stephenne | 72 | 2015 | Independent Chairman of Supervisory Board |
Michel De Wilde | 73 | 2016 | Member of Scientific Advisory Board |
Craig L. Slingluff | - | 2023 | Member of Scientific Advisory Board |
Craig A. Tooman | 58 | 2019 | Supervisory Board Member |
Stanley A. Plotkin | 91 | 2016 | Member of Scientific Advisory Board |
Fred Zepp | - | 2016 | Member of Scientific Advisory Board |
Jean-Paul Prieels | - | 2016 | Member of Scientific Advisory Board |
Christopher Karp | - | 2016 | Member of Scientific Advisory Board |
Michael Brosnan | 69 | 2023 | Independent Director of Supervisory Board |
Mathias P. Hothum | 57 | 2015 | Supervisory Board Member |
Michael P. Manns | - | 2016 | Member of Scientific Advisory Board |
Daniel Speiser | - | 2016 | Member of Scientific Advisory Board |
Nina Bhardwaj | - | 2016 | Member of Scientific Advisory Board |
Dirk Jäger | - | 2016 | Member of Scientific Advisory Board |
Karim Fizazi | 58 | 2016 | Member of Scientific Advisory Board |
Gerd Zettlmeissl | 69 | 2016 | Member of Scientific Advisory Board |
Xiao-Ning Xu | - | 2016 | Member of Scientific Advisory Board |
George R. Siber | 79 | 2016 | Member of Scientific Advisory Board |
Debra Stephanie Barker | 62 | 2022 | Supervisory Board Member |
Birgit Hofmann | - | 2024 | Member of the Supervisory Board |
Hans-Georg Rammensee | - | 2001 | Scientific Director of Immunology and Member of Scientific Advisory Board |
Mehdi Shahidi | - | - | Independent Director of Supervisory Board |
Klaus Schollmeier | 68 | 2022 | Independent Supervisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review